XORTX Sets Q4 2026 FDA IND Submission for Gout Drug XORLO™, Targets NDA in About a Year
XRTX is trading near its 52-week low of $1.59 (11% above the low) on elevated volume (21× avg).
Summary
XORTX announced plans to submit an IND for its XRx-026 gout program to the FDA in Q4 2026, with a target NDA filing in approximately one year, addressing an estimated US$700M+ U.S. market.
Key Events · Product Development and Regulatory · XRTX
-
IND Submission Planned for Q4 2026
An Investigational New Drug application for XRx-026 (XORLO™ formulation of oxypurinol) will be submitted to the FDA in the fourth quarter of 2026.
-
NDA Target Set at ~1 Year
Subject to sufficient funding and successful completion of the two-part XRX-OXY-102 clinical trial, an NDA submission is targeted in approximately one year.
-
US$700M+ Market Opportunity
The XRx-026 program is estimated to address a US$700M+ annual U.S. gout market, based on prior peak net sales for febuxostat.
-
Funding Risk Acknowledged
The NDA timeline is explicitly conditioned on 'availability of sufficient funding' — a material risk given the company's going-concern warning disclosed August 17, 2026.
Analysis · XRTX · Life Sciences
A concrete regulatory timeline has now been set for the lead gout program: an IND submission to the FDA in Q4 2026, followed by a two-part clinical trial and a targeted NDA filing in approximately one year. This marks the first public commitment to these dates. The announcement carries weight because XORTX is a micro-cap with a going-concern warning and a material weakness disclosed just last month — a credible path to an NDA is the single most important value driver for the stock. The company estimates the U.S. gout market at over US$700 million annually, based on prior febuxostat peak sales. However, the filing explicitly conditions the NDA timeline on 'sufficient funding,' and recent financial disclosures show the company is burning cash with limited runway. The IND submission itself is a regulatory milestone, not an approval — the FDA could still place the program on clinical hold or require additional studies.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, XRTX was trading at $1.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3M. The 52-week trading range was $1.59 to $7.05. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.